Inventor · disambiguated record
David Robert Micklem
Also filed as: MICKLEM DAVID · MICKLEM DAVID ROBERT
11 granted patents·9 pending applications·58 citations·filing 2008–2023
87Inventor score
Files withBERGENBIO ASA8BERGEN TEKNOLOGIOVERFORING AS4BERGEN TEKNOLOGIOVERFOERING AS3BERGENBIO AS2BERGEN TEKNOLOGIOVERFOERING ASA1
Top patents by PatentIndex Score
20 records- 0190US9975954B2Anti-Axl antibodiesBERGENBIO ASA·Filed 2015·Granted May 22, 2018·8 cites·27 claims
- 0290US9801880B2Use of kinase inhibitorsBERGENBIO AS·Filed 2014·Granted Oct 31, 2017·30 cites·8 claims
- 0384US9975953B2Anti-Axl antibodiesBERGENBIO ASA·Filed 2015·Granted May 22, 2018·7 cites·26 claims
- 0482US11198734B2Anti-Axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFOERING ASA·Filed 2017·Granted Dec 14, 2021·3 cites·31 claims
- 0582US8735064B2Methods for creating and identifying functional RNA interference elementsMICKLEM DAVID·Filed 2008·Granted May 27, 2014·7 cites·16 claims
- 0677US11035008B2Biomarkers for cancerBERGENBIO ASA·Filed 2016·Granted Jun 15, 2021·2 cites·10 claims
- 0776US2023406941A1Anti-AXL Antagonistic AntibodiesBERGEN TEKNOLOGIOVERFOERING AS·Filed 2023·Application pending·0 cites
- 0875US11732048B2Anti-axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFOERING AS·Filed 2021·Granted Aug 22, 2023·0 cites·20 claims
- 0974US2024190972A1Anti-Axl Antagonistic AntibodiesBERGEN TEKNOLOGIOVERFOERING AS·Filed 2023·Application pending·0 cites
- 1070US10208121B2Anti-Axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFORING AS·Filed 2015·Granted Feb 19, 2019·1 cites·26 claims
- 1170US2022185897A1Anti-axl antibodiesBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 1267US11584796B2Anti-Axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFORING AS·Filed 2018·Granted Feb 21, 2023·0 cites·17 claims
- 1365US11186643B2Anti-Axl antibodiesBERGENBIO ASA·Filed 2018·Granted Nov 30, 2021·0 cites·16 claims
- 1462US2018246080A1Methods using axl as a biomarker of epithelial-to-mesenchymal transitionBERGEN TEKNOLOGIOVERFORING AS·Filed 2017·Application pending·0 cites
- 1561US2015212065A1Methods using Axl as a biomarker of epithelial-to-mesenchymal transitionBERGEN TEKNOLOGIOVERFORING AS·Filed 2014·Application pending·0 cites
- 1658US9783801B2Methods for creating and identifying functional RNA interference elementsBERGENBIO ASA·Filed 2013·Granted Oct 10, 2017·0 cites·17 claims
- 1749US2023151100A1Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint ModulatorBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 1847US2012159655A1Methods using axl as a biomarker of epithelial-to-mesenchymal transitionLORENS JAMES BRADLEY·Filed 2010·Application pending·0 cites
- 1946US2021215697A1Serum BiomarkersBERGENBIO ASA·Filed 2019·Application pending·0 cites
- 2030US2017314077A1Slfn11 as biomarker for amlBERGENBIO AS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Robert Micklem files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →